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Diabetic vascular complications are associated with impaired ischaemia-driven angiogenesis. 
We recently found that reconstituted high-density lipoproteins (rHDL) rescue diabetes-impaired 
angiogenesis. microRNAs (miRNAs) regulate angiogenesis and are transported within HDL to sites 
of injury/repair. The role of miRNAs in the rescue of diabetes-impaired angiogenesis by rHDL is 
unknown. Using a miRNA array, we found that rHDL inhibits hsa-miR-181c-5p expression in vitro and 
using a hsa-miR-181c-5p mimic and antimiR identify a novel anti-angiogenic role for miR-181c-5p. 
miRNA expression was tracked over time post-hindlimb ischaemic induction in diabetic mice. Early 
post-ischaemia when angiogenesis is important, rHDL suppressed hindlimb mmu-miR-181c-5p. mmu-
miR-181c-5p was not detected in the plasma or within HDL, suggesting rHDL specifically targets 
mmu-miR-181c-5p at the ischaemic site. Three known angiogenic miRNAs (mmu-miR-223-3p, mmu-
miR-27b-3p, mmu-miR-92a-3p) were elevated in the HDL fraction of diabetic rHDL-infused mice early 
post-ischaemia. This was accompanied by a decrease in plasma levels. Only mmu-miR-223-3p levels 
were elevated in the hindlimb 3 days post-ischaemia, indicating that rHDL regulates mmu-miR-223-3p 
in a time-dependent and site-specific manner. The early regulation of miRNAs, particularly miR-
181c-5p, may underpin the rescue of diabetes-impaired angiogenesis by rHDL and has implications for 
the treatment of diabetes-related vascular complications.
Diabetic patients suffer from poor outcomes post myocardial infarction due to impaired coronary collateral for-
mation post-occlusion1. Diabetics also experience higher rates of peripheral limb ulceration and amputation 
arising from peripheral vascular disease2,3. Despite advances in the treatment of diabetic vascular complications, 
many patients remain refractory to current treatment approaches, highlighting the need for alternate therapies. 
The clinical severity of occlusive arterial disease in diabetic patients has, in part, been attributed to impaired 
ischaemia-driven angiogenesis, which involves a complex orchestration of signaling pathways and cellular events, 
beginning with the induction of the hypoxic transcription factor HIF-1α, which promotes the expression of 
VEGFA, a potent angiogenic mediator. In diabetes, however, HIF-1α stability4,5 and VEGFA production and 
signalling sensitivity6 are suppressed, causing the angiogenic response to ischaemia to be impaired.
MicroRNAs (miRNAs) are small non-coding RNAs that post-transcriptionally regulate gene expression by 
targeting mRNAs causing either partial or complete translational repression. miRNAs can simultaneously con-
trol multiple genes; therefore the modulation of a single miRNA has the ability to correct complex diseases7. This 
makes miRNA modulation potentially more powerful than single gene targeting strategies. Circulating miR-
NAs have emerged as novel biomarkers in angiogenesis-associated diseases, such as cancer and cardiovascular 
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disease (CVD)8–12. miRNAs have been implicated in HIF-1α-dependent angiogenic regulation13 and can drive 
pro- or anti-angiogenic effects depending on the downstream targets. miR-27b, for example, is an established 
pro-angiogenic miRNA in CVD and cancer14, while miR-223 has anti-angiogenic properties via regulation of the 
RPS6KB1/HIF-1α pathway15. These studies highlight the potential of miRNAs to act as molecular therapeutic 
targets for complex diseases such as diabetes-impaired angiogenesis.
HDL has potent anti-diabetic properties and is associated with reduced diabetic vascular complications. Low 
HDL levels are an independent risk factor for the development of type 2 diabetes mellitus (T2DM)16 and are asso-
ciated with an increased risk of microvascular disease in T2DM patients17. We have previously shown that HDL 
augments ischaemia-driven angiogenesis18,19, an effect that is retained in aged mice20. We recently discovered that 
rHDL rescues diabetes-impaired angiogenesis through its ability to increase HIF-1α stability and VEGFA pro-
duction21. The mechanism by which rHDL regulates angiogenesis in diabetes still remains to be fully elucidated, 
although miRNAs present as highly likely contributors to these effects. Furthermore, HDL is known to transport 
endogenous miRNAs, delivering them to recipient cells to cause significant functional effects22,23.
Accordingly, we sought to investigate the regulation of miRNAs by rHDL in diabetes-impaired angiogen-
esis. Using a miRNA array, we initially identified 4 miRNAs that were regulated by rHDL. In vitro validation 
studies then revealed a novel anti-angiogenic role for hsa-miR-181c-5p. In vivo studies in diabetic mice tracked 
the miRNA expression over time following the induction of hindlimb ischaemia. It was found that mmu-miR-
181c-5p expression in the hindlimb was inhibited early post-ischaemia in diabetic mice infused with rHDL. 
Whilst mmu-miR-181c-5p was not detected in the HDL fraction of the plasma, mmu-miR-223-3p, mmu-miR-
27b-3p and mmu-miR-92a-3p were all elevated in the HDL fraction in rHDL-infused mice early post-ischaemia. 
mmu-miR-223-3p levels were also elevated in the ischaemic tissue mid-phase post-ischaemia, suggesting rHDL 
infusions regulate mmu-miR-223-3p in both a time-dependent and site-specific manner. Taken together, our 
studies show that early regulation of miRNAs, and in particular miR-181c-5p, may underpin the ability of rHDL 
to rescue diabetes-impaired angiogenesis.
Results
Identification of miRNAs involved in the angiogenic action of rHDL. We have previously shown 
that rHDL conditionally regulates angiogenesis, inhibiting inflammatory-driven angiogenesis18 and augmenting 
hypoxia-mediated angiogenesis18,19. We now sought to determine the role of miRNAs in the angiogenic action 
of HDL. A global profile of 874 miRNA targets were assessed using the TaqMan low-density arrays (TLDA) in 
HCMECs treated with rHDL (20 μM) or PBS (vehicle), prior to hypoxic exposure (1% O2) or stimulation with the 
inflammatory cytokine TNFα (0.6 ng/mL). The array data showed the pro-angiogenic miRNA hsa-miR-27b-3p 
was suppressed by rHDL in both hypoxia and inflammation (Supplemental Fig. 1). In cells exposed to hypoxia, 
rHDL also suppressed hsa-miR-433-3p and hsa-miR-874-3p, while in inflammation hsa-miR-181c-5p was sup-
pressed. To confirm the array data, we then assessed the levels of these miRNAs in cells treated with rHDL in 
hypoxia. In contrast to the original TLDA findings, we found that rHDL only suppressed hsa-miR-181c-5p levels 
(Fig. 1a) but not hsa-miR-27b-3p, hsa-miR-433-3p or hsa-miR-874-3p in both normoxia and hypoxia. When 
cells were transduced with an adenovirus to overexpress HIF-1α, hsa-miR-27b-3p levels were elevated (Fig. 1b) 
supporting its known pro-angiogenic role in hypoxia, and hsa-miR-181c-5p levels were inhibited indicating an 
anti-angiogenic role. Exposure to high glucose (48 h) elevated hsa-miR-181c-5p, but not hsa-miR-27b-3p levels 
and pre-incubation with rHDL (20 μM) suppressed this induction (Fig. 1c). Both hsa-miR-27b-3p and hsa-miR-
181c-5p levels were inhibited by rHDL irrespective of glucose conditions.
miR-181c-5p has an inhibitory role in angiogenesis. While miR-27b is an established pro-angiogenic 
miRNA14,24, very little is known about the role of miR-181c-5p in angiogenesis. To directly assess the effects of 
miR-181c-5p on angiogenesis, cells were transfected with either hsa-miR-181c-5p mimics or antimiRs to over-
express or inhibit hsa-miR-181c-5p (Supplemental Fig. 2). 48 hours post-transfection, cells were used for an in 
vitro tubulogenesis assay. We found that endothelial cells overexpressing hsa-miR-181c-5p had a reduced capacity 
to form tubules while conversely, when hsa-miR-181c-5p was inhibited, the cells had an increased capacity for 
tubule formation when compared to their respective transfected negative controls (Fig. 2a). Furthermore, the 
mean tubule length in cells with increased hsa-miR-181c-5p activity is shorter compared to the negative mimic 
control (Fig. 2b). However, when hsa-miR-181c-5p activity is inhibited, these cells formed longer tubules com-
pared to the negative antimiR control. Finally, the mean number of branch points were also reduced in hsa-miR-
181c-5p mimic cells while hsa-miR-181c-5p antimiR cells had more branch points (Fig. 2c).
Consistent with these findings, we found that overexpression of hsa-miR-181c-5p caused a small but sig-
nificant reduction in VEGFA protein levels (Fig. 3a) while inhibition of hsa-miR-181c-5p elevated VEGFA 
protein (Fig. 3b). Interestingly, VEGFA mRNA levels were increased in cells transfected with either hsa-miR-
181c-5p mimics or antimiRs (Supplemental Fig 4a and b). To determine if VEGFA is a direct target of hsa-miR-
181c-5p, luciferase reporter studies were performed. We found that there was increased luciferase activity in cells 
co-transfected with the 3′UTR of VEGFA and hsa-miR-181c-5p mimics (Supplemental Fig. 4c); however, no 
differences were observed when hsa-miR-181c-5p was inhibited (Supplemental Fig. 4d). Sequence alignment of 
3′UTR of VEGFA and hsa-miR-181c-5p seed sequence reveals that there is a low level of consensus with VEGFA 
(Supplemental Fig. 4e). These findings suggest that the effect of hsa-miR-181c-5p on VEGFA expression is not at 
a direct transcriptional level but may be indirectly influenced at a translational level.
rHDL augments diabetes-impaired blood flow perfusion and neovascularisation. We next 
assessed the regulation of miRNAs by rHDL in vivo using the hindlimb ischaemia model of ischaemia-mediated 
angiogenesis. Consistent with our previous findings21, rHDL infusions rescued diabetes-impaired blood flow 
perfusion, a marker of angiogenesis, in streptozotocin-rendered diabetic mice (Fig. 4a). The effects of rHDL 
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were independent of changes in glucose and lipid levels (Supplemental Tables 1 and 2). 3 days post-ischaemic 
induction, diabetic rHDL-infused mice had higher capillary density compared to the diabetic PBS mice (Fig. 4b), 
however there was no difference between the non-diabetic and diabetic PBS animals. Diabetes impaired capillary 
Figure 1. Identification of miRNAs involved in the angiogenic action of rHDL. The expression levels of 
miRNAs were assessed by qRT-PCR in HCAECs that were either (a) treated with rHDL (20 μM, final apoA-I 
concentration) or PBS (vehicle) prior to normoxia/hypoxia exposure; (b) transduced with adenovirus (1 × 106 
viral particles/mL) overexpressing HIF-1α (AdHIF-1α) or GFP (AdGFP, adenoviral control) for 48 hours; 
or (c) treated with rHDL (20 μM) or PBS (vehicle) then exposed to glucose conditions (5–25 mM, media 
supplemented with D-glucose) for 48 hours. Relative changes in miRNA levels were normalised using the 
ΔΔCt method to RNU48. Results shown are the mean ± SEM of three independent experiments. *P < 0.05, 
**P < 0.01, ***P < 0.001, ****P < 0.0001.
www.nature.com/scientificreports/
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formation at the later stages (days 7 and 10) post-ischaemic induction. However, an increase in the number of 
capillaries formed per myocyte was still observed in diabetic animals treated with rHDL. The number of arterioles 
formed were also elevated in these animals in the mid-late stages post-ischaemia (Fig. 4c).
Figure 2. miR-181c-5p has an inhibitory role in angiogenesis. HCAECs were transfected with either hsa-miR-
181c-5p mimics (20 nM), antimiRs (100 nM) or appropriate negative controls using Lipofectamine RNAiMax 
for 6 hours. 48 hours post-transfection, transfected HCAECs were seeded at 8 × 103 cells/well (5 wells/
condition) on polymerised growth factor reduced Matrigel and incubated for 5–6 hours. Non-transfected cells 
were included in the Matrigel assay. The entire well (8–12 fields of view) was photographed at 5X magnification 
on multiple focal fields under light microscopy and analysed using ImageJ (National Institutes of Health) for (a) 
number of tubules, (b) mean tubule length and (c) mean branch point. *P < 0.05, ****P < 0.0001.
www.nature.com/scientificreports/
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mmu-miR-181c-5p is suppressed by rHDL early post-ischaemia in diabetic mice. Studies have 
reported the temporal expression of miRNAs in angiogenesis25. miRNA levels were measured at the site of ischae-
mia, within the HDL fraction and in the plasma in cohorts of mice at time points reflective of early (0–24 h), mid 
(3–7d) and late (10d) stages of angiogenesis to determine if the pro-angiogenic effects of HDL in diabetes in vivo 
is facilitated by regulation of miRNAs at the site of ischaemic injury or within the HDL particle.
We firstly tracked the expression levels of our novel anti-angiogenic miRNA, mmu-miR-181c-5p in the ischae-
mic hindlimb. Early post-ischaemia (6 h) when the induction of angiogenesis is most important, rHDL sup-
pressed hindlimb mmu-miR-181c-5p levels (Fig. 5a), which were paralleled with an elevation in Vegfa levels 
(Fig. 5b). mmu-miR-181c-5p was not detected in the HDL fraction or in the plasma, suggesting that the effects of 
rHDL on mmu-miR-181c-5p is focussed at the site of ischaemia.
rHDL increases mmu-miR-223-3p levels in the HDL particle 6 hours post-ischaemia and aug-
ments hindlimb mmu-miR-223-3p levels 3 days post-ischaemia. In addition to mmu-miR-181c-5p, 
we also determined the effect of rHDL on three other miRNAs: mmu-miR-223-3p, mmu-miR-27b-3p and 
mmu-miR-92a-3p. These miRNAs were selected based on previous evidence for either a role in angiogenesis 
or their presence and transportation in HDL. HDL transport of endogenous miRNAs is a known mechanism 
for miRNA delivery to recipient cells with functional targeting capabilities23. We first assessed the expression 
levels of mmu-miR-223-3p, an anti-angiogenic miRNA26 that has previously been shown to be carried by HDL23. 
Six hours post-ischaemic induction, there was a 5.8-fold increase in the levels of mmu-miR-223-3p within the 
HDL fraction of diabetic mice infused with rHDL (Fig. 6a). Plasma mmu-miR-223-3p levels in the diabetic PBS 
infused mice were significantly elevated 24 hours post-ischaemia. This elevation in plasma mmu-miR-223-3p lev-
els did not occur in mice infused with rHDL (Fig. 6b). Whilst diabetic PBS control animals had elevated hindlimb 
mmu-miR-223-3p levels in the early-mid stages (24 h and day 3) post-ischaemia, compared to the 0 h timepoint 
(Fig. 6c), infusions of rHDL caused a substantial 2.5-fold increase in mmu-miR-223-3p levels in the tissue at 
day 3. This may suggest that infusions of rHDL are increasing hindlimb levels of the anti-angiogenic miRNA 
mmu-miR-223-3p at a timepoint in which the initial need for an induction in angiogenesis was starting to decline 
and the remodelling events were commencing.
rHDL induces mmu-miR-27b-3p and mmu-miR-92a-3p levels in the HDL particle 6 hours 
post-ischaemia. We then sought to determine if rHDL also regulates two other angiogenic miRNAs: 
mmu-miR-27b-3p, a pro-angiogenic miRNA24 that was identified in the original miRNA profile study to be reg-
ulated by rHDL and mmu-miR-92a-3p, an established anti-angiogenic miRNA27. rHDL promoted an increase 
in both mmu-miR-27b-3p (Fig. 7a) and mmu-miR-92a-3p (Fig. 7b) levels within the HDL fraction 6 hours 
post-ischaemia. A decrease in plasma miRNA levels was observed in rHDL-treated mice at the 24-hour timepoint 
(mmu-miR-27b-3p: Fig. 7c and mmu-miR-92a-3p: Fig. 7d). However, no differences were observed in tissue 
miRNA levels for both these miRNAs (Fig. 7e and f). Our findings suggest that whilst rHDL is able to increase the 
Figure 3. miR-181c-5p regulates VEGFA protein levels. HCAECs were transfected with either hsa-miR-
181c-5p mimics (20 nM), antimiRs (100 nM) or appropriate negative controls using Lipofectamine RNAiMax 
for 6 hours. 48 hours post-transfection, protein lysates were isolated and VEGFA protein levels were measured 
by Western blot in cells transfected with (a) mimics or (b) antimiRs. The cropped blots are used in the figure, 
and the full-length blots are presented in Supplemental Fig. 3. Results shown are the mean ± SEM of three 
independent experiments. *P < 0.05.
www.nature.com/scientificreports/
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levels of mmu-miR-27b-3p and mmu-miR-92a-3p in the HDL fraction, the lack of change at the ischaemic site 
implies they do not play a significant role in the augmentation of angiogenesis in diabetes by rHDL.
Discussion
We have previously reported that rHDL rescues diabetes-impaired angiogenesis via salutary effects on the clas-
sical HIF-1α/VEGFA angiogenic signalling pathway21, however, the involvement of miRNAs is unknown. This 
study identified and confirmed a novel anti-angiogenic role for miR-181c-5p using mimics and antimiRs, which 
is also inhibited by rHDL in vitro. Infusions of rHDL to diabetic mice suppressed mmu-miR-181c-5p levels in 
Figure 4. rHDL augments diabetes-impaired blood flow perfusion and neovascularisation. Non-diabetic 
and diabetic C57Bl/6 J mice underwent femoral artery and vein ligation. Mice received i.p. injections of rHDL 
(400 μg/injection, final apoA-I concentration) or PBS (vehicle) on alternate days one week prior to surgery until 
sacrifice. (a) Hindlimb blood reperfusion was determined by laser Doppler perfusion imaging; representative 
images show high (red) to low (blue) blood flow at Day 10. Laser Doppler perfusion index was determined as 
a ratio of the ischaemic (ISC): non-ischaemic (NON) hindlimb. Grey triangles, Non-Diabetic PBS mice; black 
circles, Diabetic PBS mice; white squares, Diabetic rHDL mice. Gastrocnemius muscle sections were stained 
for capillaries (CD31+, stained red, denoted by white arrows), arterioles (SMC α-actin+, stained green, denoted 
by green arrows) and myocytes (laminin+, stained blue). Scale bar: 100 μm. (b) Capillary density (CD31+/
myocytes) and (c) arteriolar density (SMC α-actin+/myocytes) was determined as a ratio of ischaemic: non-
ischaemic hindlimb. Results shown are the mean ± SEM (n = 5–6/group). #P < 0.05, ##P < 0.01 vs. Non-Diabetic 
PBS; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 vs. Diabetic PBS.
www.nature.com/scientificreports/
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the hindlimb tissue in the first 6 hours post-ischaemia. Analysis of other angiogenic miRNAs revealed that rHDL 
infusions increased mmu-miR-223-3p levels in the HDL fraction 6 hours post-ischaemia and in the hindlimb 
3 days post-ischaemia. This suggests that rHDL infusions influence differential and site-specific expression of 
mmu-miR-223-3p in a time-dependent manner. The increase in hindlimb mmu-miR-223-3p may serve to sup-
press the initial induction of angiogenesis once capillary and arteriolar density are sufficient for adequate per-
fusion. Taken together, these findings support a role for miRNAs, particularly miR-181c-5p, in the rescue of 
diabetes-impaired angiogenesis by rHDL. Inhibition of miR-181c-5p may present as a potential therapeutic strat-
egy for the treatment of diabetes-related vascular complications.
We have previously found that rHDL augments hypoxia-induced angiogenesis18,19. Using a miRNA array, we 
identified 4 miRNAs (hsa-miR-27b-3p, hsa-miR-181c-5p, hsa-miR-433-3p and hsa-miR-874-3p), that were reg-
ulated by rHDL. However, only hsa-miR-27b-3p and hsa-miR-181c-5p were regulated by HIF-1α overexpression 
and suppressed by rHDL in high glucose. While miR-27b-3p is an established pro-angiogenic miRNA14,24, miR-
181c-5p had no known role in angiogenesis. To date, studies on miR-181c have focused on its link to Alzheimer’s 
disease and cancer progression28. miR-181c-modulated genes converge on signalling cascades relevant to neurite 
and synapse development, suggesting a role in cortical neuronal maturation29. Consistent with a role in angio-
genesis, miR-181c is implicated in the development and progression of pancreatic cancer30 and inflammatory 
breast cancer31. Furthermore, differential profiling of miRNAs in placental development found that miR-181c 
was significantly upregulated in third trimester placentas32. This study has directly demonstrated for the first time 
that miR-181c-5p is an anti-angiogenic miRNA, where overexpression of hsa-miR-181c-5p inhibited endothe-
lial vascular network formation while hsa-miR-181c-5p inhibition promoted tubule formation in vitro. In vivo, 
rHDL suppressed mmu-miR-181c-5p locally in the ischaemic hindlimb tissue of diabetic mice in the early phase 
post-ischaemia. mmu-miR-181c-5p levels were also reduced 24 hours post-ischaemia in the diabetic PBS animals, 
suggesting that miR-181c-5p suppression is critical to augment angiogenesis in the early stages post-ischaemia 
when the need for angiogenesis is greatest. The earlier suppression of mmu-miR-181c-5p by rHDL in the 
ischaemic tissue may trigger a more rapid angiogenic response to the ischaemic stimulus. mmu-miR-181c-5p 
expression was not detected in either the HDL fraction or in the circulation, suggesting that the regulation of 
mmu-miR-181c-5p expression by rHDL is restricted to the site of tissue ischaemia.
Figure 5. mmu-miR-181c-5p is suppressed by rHDL early post-ischaemia in diabetic mice. Diabetic C57Bl/6 J 
mice received i.p. injections of rHDL (400 μg/injection, final apoA-I concentration) or PBS (vehicle) on 
alternate days one week prior to surgery until sacrifice. (a) Hindlimb mmu-miR-181c-5p levels, normalised to 
RNU68. (b) Hindlimb Vegfa mRNA levels, normalised to 36B4. ***P < 0.001 vs. relative timepoint Diabetic 
PBS; #P < 0.05 ####P < 0.001 vs. 0 h Diabetic PBS; ^^^^P < 0.0001 vs. 0 h Diabetic rHDL.
www.nature.com/scientificreports/
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This study also explored the effect of rHDL on three established angiogenic miRNAs: miR-223-3p, miR-
27b-3p and miR-92a-3p. HDL transport of endogenous miRNAs is a mechanism for their delivery to recip-
ient cells with functional targeting capabilities23. Infusions of rHDL into mice causes distinctly different 
miRNA profiles between normal and atherogenic models23. miR-223 was found to be the most abundant 
HDL-associated miRNA in familial hypercholesterolaemia23 and its delivery to endothelial cells was shown to 
confer anti-inflammatory effects22. In the current study, mmu-miR-223-3p levels were elevated in the HDL frac-
tion of diabetic rHDL-infused mice 6 hours post-ischaemia, which was accompanied with a reduction in circu-
lating plasma levels at 24 hours. Animals treated with rHDL had elevated hindlimb mmu-miR-223-3p levels at 
the mid-phase post-ischaemia (3 days). Previous studies have shown that miR-223 is an anti-angiogenic miRNA, 
where overexpression of miR-223 suppressed angiogenic pathways including VEGFA stimulated phosphorylation 
of Akt, proliferation and migration15,26. The anti-angiogenic effects of miR-223 were also demonstrated in vivo 
with enhanced perfusion recovery seen in miR-223−/y mice post-ischaemic induction26. We postulate that the 
Figure 6. rHDL increases mmu-miR-223-3p levels in the HDL particle 6 hours post-ischaemia and augments 
hindlimb mmu-miR-223-3p levels 3 days post-ischaemia. Diabetic C57Bl/6 J mice received i.p. injections 
of rHDL (400 μg/injection, final apoA-I concentration) or PBS (vehicle) on alternate days one week prior 
to surgery until sacrifice. mmu-miR-223-3p levels, normalised to RNU68 in the (a) HDL fraction, (b) 
plasma and (c) tissue. Results shown are the mean ± SEM (n = 5–6/group). **P < 0.01, ****P < 0.0001 vs. 
relative timepoint Diabetic PBS; ##P < 0.01, ###P < 0.001, ####P < 0.0001 vs. 0 h Diabetic PBS; ^^P < 0.01, 
^^^^P < 0.0001 vs. 0 h Diabetic rHDL.
www.nature.com/scientificreports/
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increase in hindlimb mmu-miR-223-3p levels seen in the HDL-treated mice may serve as a negative regulator 
of the angiogenic response during the mid-stage post-ischaemia, when the early-stage induction of neovascu-
larisation is complete and a tapering of pro-angiogenic processes is required as the tissue remodelling phase 
approaches.
Our miRNA profile array found that rHDL suppressed hsa-miR-27b-3p in high glucose conditions in vitro. 
miR-27b was shown to improve tissue revascularisation and blood flow perfusion in a non-diabetic mouse model 
of critical limb ischaemia14 and augmented wound perfusion, capillary formation and healing in diabetic mice33. 
As rHDL rescues both diabetes-impaired ischaemia-induced neovascularisation and wound angiogenesis and 
healing21, we proposed that miR-27b may mediate the pro-angiogenic effects of rHDL. miR-92a is an established 
Figure 7. rHDL induces mmu-miR-27b-3p and mmu-miR-92a-3p levels in the HDL particle 6 hours 
post-ischaemia. Diabetic C57Bl/6 J mice received i.p. injections of rHDL (400 μg/injection, final apoA-I 
concentration) or PBS (vehicle) on alternate days one week prior to surgery until sacrifice. mmu-miR-27b-3p 
and mmu-miR-92a-3p levels, normalised to RNU68 in the (a,b) HDL fraction, (c,d) plasma and (e,f) tissue 
respectively. Results shown are the mean ± SEM (n = 5–6/group). *P < 0.05, **P < 0.01, ****P < 0.0001 vs. 
relative timepoint Diabetic PBS; #P < 0.05, ####P < 0.0001 vs. 0 h Diabetic PBS; ^^P < 0.01, ^^^^P < 0.0001 vs. 
0 h Diabetic rHDL.
www.nature.com/scientificreports/
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anti-angiogenic miRNA34, with pre-clinical studies showing that miR-92a inhibition enhanced blood vessel 
growth and functional recovery of damaged tissue in mouse models of limb ischaemia and myocardial infarc-
tion27. While rHDL increased both mmu-miR-27b-3p & mmu-miR-92a-3p levels in the HDL particle, there was 
no change at the ischaemic site, suggesting that these miRNAs may not be critical in the action of rHDL in a 
diabetic milieu. The importance of elevating mmu-miR-27b-3p and mmu-miR-92a-3p in the HDL fraction with 
no change at the site of ischaemia is unclear. It may suggest that these miRNAs are delivered to other sites such as 
the liver, the organ that HDL is metabolised through, with studies demonstrating hepatic miR-27b expression is 
responsive to lipid levels and controls multiple genes critical to dyslipidaemia23.
This is the first study to comprehensively track over time the regulation of miRNAs in the rescue of 
diabetes-impaired angiogenesis by rHDL. We found that the regulation of the miRNAs by rHDL occurs early 
post-ischaemia at the tissue site and in the HDL fraction. We posit that this early regulation by rHDL, particu-
larly the suppression of mmu-miR-181c-5p at the ischaemic tissue site may, at least in part, contribute to the 
pro-angiogenic actions of HDL in diabetes. A key hallmark of diabetes impaired neovascularisation is reduced 
VEGFA production and sensitivity6. We previously found that rHDL rescues diabetes-impaired neovasculari-
sation by augmenting VEGFA production and VEGFR2 signalling21. It has been previously reported that over-
expression of two VEGFA isoforms (VEGFA165 and VEGFA206) resulted in the downregulation of miR-181c 
expression in a lung adenocarcinoma line in vitro35 but whether VEGFA is a downstream target of miR-181c is 
unknown. Cells transfected with either hsa-miR-181c-5p mimics or antimiRs had small but significant differ-
ences in VEGFA protein levels. However, qPCR and luciferase assays coupled with sequence alignment showed 
that VEGFA is not a direct transcriptional target of hsa-miR-181c-5p. Bioinformatics miRNA pathway analysis 
using DIANA-mirPath36 encompassing 3 databases (TargetScan, microT-CDS and Tarbase) predicted that miR-
181c-5p targets genes that contribute to key cellular processes involved in angiogenesis including NOS regulation, 
TGF-β1 signalling, FGF signalling and post-translational protein modification. Taken together, we postulate that 
the effect of miR-181c-5p on VEGFA expression is not at a direct transcriptional level but may be indirectly influ-
enced at a translational level by alternate signalling pathways. Furthermore, VEGFA mediates its pro-angiogenic 
effects by binding to VEGFR2 to trigger autophosphorylation of the receptor, activating downstream intracellular 
pathways which ultimately contribute to angiogenesis37. Therefore, we believe that the small translational effects 
of mir-181c-5p on VEGFA protein could have striking downstream effects on angiogenesis. Previous studies have 
found that miR-181c acts as a control point in the phosphorylation of Akt38, a key signalling protein for angio-
genesis. rHDL augments the Akt signalling pathway in hypoxia39 and high glucose21. Furthermore, inhibition of 
the Akt signalling pathway abrogated the pro-angiogenic effects of rHDL in hypoxia19. These studies add further 
support for a role of miR-181c-5p in angiogenesis and suggest that the downstream targets of miR-181c-5p may 
not be restricted to just VEGFA but other critical angiogenic signalling proteins.
In conclusion, we have identified a novel anti-angiogenic miRNA, miR-181c-5p, first using array analysis 
and confirmed using hsa-miR-181c-5p mimics and antimiRs. We have tracked changes in miRNA expression 
in diabetic mice in response to ischaemia and tested the effect of rHDL infusions (Fig. 8). We find changes in 
miRNAs and they predominantly occur in the early phase post-ischaemia where infusions of rHDL cause: (1) 
a suppression in mmu-miR-181c-5p levels in the ischaemic hindlimb, consistent with an anti-angiogenic role 
for miR-181c-5p; (2) an elevation in mmu-miR-223-3p, mmu-miR-27b-3p and mmu-miR-92a-3p levels in the 
HDL fraction; and a (3) reduction in mmu-miR-223-3p, mmu-miR-27b-3p and mmu-miR-92a-3p plasma lev-
els. However, only mmu-miR-223-3p levels were elevated at the ischaemic site in the mid-stage post-ischaemia. 
Elevated mmu-miR-223-3p during the mid-ischaemic phase may serve to suppress the initial induction of angi-
ogenesis once capillary and arteriolar density have reached levels sufficient to restore adequate perfusion. This 
study provides a greater understanding of the mechanisms by which rHDL rescues diabetes-impaired angiogen-
esis; particularly the involvement of miRNAs, which may provide alternate therapeutic targets for the improve-
ment of diabetes-associated vascular complications and the translation of HDL.
Methods
Preparation of discoidal reconstituted HDL. apoA-I was isolated from pooled samples of multiple 
donated plasma samples from healthy humans obtained from the Australian Red Cross (Supply Agreement 
14-02NSW-04) by ultracentrifugation and anion-exchange chromatography as described previously18,21. Approval 
was granted by the Sydney Local Health District Human Ethics Review Committee (HREC\EXECOR\15-06) and 
conformed to the Declaration of Helsinki, with informed consent obtained at the time of collection. Discoidal 
reconstituted HDL (rHDL) was prepared by complexing apoA-I with 1-palmitoyl-2-linoleoyl-phosphatidylcho-
line (PLPC).
Profiling of miRNAs. Human cardiac microvascular endothelial cells (HCMECs, PromoCell) were cultured 
in EGM-2MV media and used at passage 5. Cells were plated at 8 × 104 cells/well and grown to 60% confluency. 
HCMECs were treated with rHDL (20 μM, final apoA-I concentration) or PBS (vehicle control) for 24 hours then 
exposed to two forms of angiogenic stimuli: (1) hypoxia (1% O2 balanced with N2) for 8 hours; or (2) stimulation 
with the inflammatory cytokine TNFα (0.6 ng/mL) for 4.5 hours. Two donors were used and the experiments 
were performed independently 5 times.
Expression of 874 miRNAs was performed by reverse transcription and quantitative real-time PCR (qPCR) 
using the Megaplex TaqMan Low Density Human miRNA Array (TLDA). Total RNA was extracted using TRI 
reagent. 1000 ng total RNA was retro-transcribed using stem-loop primers and the amplified product was loaded 
onto the TLDA and signals were detected by qPCR. The fold change of miRNAs was calculated using the compar-
ative Cq method (2−ΔΔCq) and normalised to endogenous U6 internal reference gene.
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Validation of miRNA profiling data. Human coronary artery endothelial cells (HCAECs, Cell 
Applications) were cultured in MesoEndo growth medium and used at passages 4–6. To confirm the miRNA pro-
filing data, cells were either (1) treated with rHDL (20 μM, final apoA-I concentration) or PBS (vehicle) prior to 
normoxia/hypoxia exposure; (2) transduced with adenovirus (1 × 106 viral particles/mL) overexpressing HIF-1α 
(AdHIF-1α) or GFP (AdGFP, adenoviral control) for 48 hours; or (3) treated with rHDL (20 μM) or PBS (vehicle) 
then exposed to glucose conditions (5–25 mM, media supplemented with D-glucose) for 48 hours. Each experi-
ment was conducted three times independently in triplicate.
MicroRNA-181c-5p transfection. HCAECs were seeded at 1.5 × 105 cells/well and grown to 80% con-
fluency. HCAECs were transfected with hsa-miR-181c-5p mimics (20 nM), antimiRs (100 nM) or appropriate 
controls using Lipofectamine RNAiMax for 6 hours. 48 hours post-transfection, cells were assessed for Matrigel 
tubulogenesis assays, VEGFA protein and VEGFA mRNA levels. Each experiment was conducted five times inde-
pendently in triplicate.
Matrigel tubulogenesis assay. Transfected HCAECs were seeded at 8 × 103 cells/well (5 wells/condition) 
on polymerised growth factor reduced Matrigel and incubated for 5–6 hours. Non-transfected cells were included 
in the Matrigel assay. The entire well (8–12 fields of view) was photographed at 5X magnification on multiple focal 
fields under light microscopy and analysed using ImageJ (National Institutes of Health) for number of tubules, 
mean tubule length and mean branch point.
Western blot. Protein was extracted using RIPA lysis buffer21 and subjected to Western blot analysis and 
probed with VEGFA antibody (ab46154, Abcam). Even protein loading was confirmed by α-tubulin (ab40742, 
Abcam).
Luciferase reporter assay. Ad293 cells were co-transfected with 150 ng luciferase reporter construct con-
taining 3′-untranslated region (3′UTR) of VEGFA (GeneCopoeia) and with either hsa-miR-181c-5p mimics, 
antimiRs or respective negative controls. Luciferase activity was measured 48 hours after transfection using the 
Secrete-Pair™ Dual Luminescence Assay Kit.
Animals. All experimental procedures were conducted with approval from the Sydney Local Health District 
Animal Welfare Committee (#2015/038) and conformed to the Guide for the Care and Use of Laboratory Animals 
Figure 8. The regulation of miRNAs by rHDL in diabetes-impaired angiogenesis. rHDL induces changes in the 
expression of miRNAs in diabetic mice. These changes predominantly occur in the early phase post-ischaemic 
induction where (1) mmu-miR-181c-5p levels are suppressed in the ischaemic hindlimb; (2) mmu-miR-223-3p, 
mmu-miR-27b-3p and mmu-miR-92a-3p are elevated in the HDL fraction; and (3) plasma mmu-miR-223-3p, 
mmu-miR-27b-3p and mmu-miR-92a-3p levels are reduced. However, only mmu-miR-223-3p levels were 
elevated at the ischaemic site in the mid-stage post-ischaemia, which may serve to suppress the initial induction 
of angiogenesis once capillary and arteriolar density have reached levels sufficient to restore adequate perfusion. 
In vitro gain-of-function (mimics) and loss-of-function (antimiRs) studies suggest that miR-181c-5p may 
have indirect effects on VEGFA at a translational level, supporting an anti-angiogenic role for miR-181c-5p in 
angiogenesis, which may contribute towards increased neovascularisation in the mid phase post-ischaemia and 
culminating in blood flow perfusion at the later stage. ↑ and ↓ denotes the effects of rHDL.
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(United States National Institute of Health). 8-week-old male C57BL/6J mice were rendered diabetic 2 weeks 
prior to surgery by a bolus i.p. injection of streptozotocin (165 μg/g).
Hindlimb ischaemia model. The hindlimb ischaemia model was conducted as described previously 
to ensure ischaemia in the distal regions of the hindlimb18,21,40. The left femoral artery and vein were ligated 
and excised proximal to the profunda femoris and epigastrica arteries and distally to the popliteal fossa40. Mice 
(n = 5–6/group) received three i.p. injections of either rHDL (400 μg/injection, final apoA-I concentration) or 
PBS (vehicle) on alternate days one week prior to surgery until sacrifice. Hindlimb blood reperfusion was deter-
mined by laser Doppler perfusion imaging prior to and immediately following surgery and then at days 1, 3, 5, 7, 
and 10 post-ischaemic induction. Parallel cohorts of mice were assessed at baseline (0 hours), early (6 & 24 hours), 
mid (3 & 7 days) and later (10 days) time points post-ischaemia.
Plasma glucose and lipid concentrations. Glucose concentrations were measured using a glucometer 
(Accu-Chek Performa). Total, HDL, and LDL cholesterol concentrations on mouse plasma were determined 
enzymatically (Roche Diagnostics). HDL cholesterol concentrations were determined following polyethylene 
glycol precipitation of apoB-containing lipoproteins18,21.
Immunocytochemistry. Fresh frozen 5-μm sections of gastrocnemius muscle from ischaemic and 
non-ischaemic hindlimbs of mice at 3, 7 and 10 days post-ischaemia were stained to detect the number of CD31+ 
capillaries (ab25644, Abcam) and α-SMC+ arterioles (F3777-2M, Sigma) per myocyte (laminin; Abcam). Three 
separate regions within each section were imaged at 10X magnification and repeated across 2 slides with 3 sec-
tions per sample. All images were then analysed digitally on Image-Pro Premier software to determine capillary 
density (CD31+ capillaries/myocyte) and arteriolar density (α-SMC+ arterioles/myocyte).
RNA extraction, reverse transcription and qRT-PCR. Total RNA was isolated using TRI reagent and 
up to 1000 ng total RNA was reverse transcribed using the miScript II RT synthesis kit. qPCR was used to deter-
mine the expression levels of (1) hsa-miR-27b-3p, hsa-miR-181c-5p, hsa-miR-433-3p and hsa-miR-874-3p in the 
treated cells, and (2) mmu-miR-181c-5p, mmu-miR-223-3p, mmu-miR-27b-3p and mmu-miR-92a-3p in the 
HDL fraction, circulating plasma and gastrocnemius muscles using miScript primer assays (Qiagen). Relative 
changes in miRNA levels were normalised using the ΔΔCt method to RNU48 for treated cells or RNU68 for the 
murine samples. qPCR was also performed for (1) VEGFA levels (normalised to B2M) in the hsa-mir-181c-5p 
transfected cells and (2) Vegfa levels in the gastrocnemius muscles and normalised to murine 36B4 using primers 
designed previously21.
Statistical analysis. Data are expressed as mean ± SEM. Differences between treatment groups were calcu-
lated using a one-way ANOVA (Tukey’s post hoc comparison test) or Student’s t-test. A two-way ANOVA (Tukey’s 
post hoc comparison test) was performed when comparing data at multiple time points. Significance was set at a 
two-sided P < 0.05.
Data Availability
The datasets generated or analysed during the current study are available from the corresponding author on 
reasonable request.
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